Skip to main content Back to Top


Rabies Vaccine

Products Affected - Description

    • Imovax intramuscular injection, Sanofi Pasteur, NDC 49281-0250-51
    • RabAvert intramuscular injection, GlaxoSmithKline Vaccines, NDC 58160-0964-12

Reason for the Shortage

    • Sanofi Pasteur has Imovax rabies vaccine on shortage due to increased demand.
    • GlaxoSmithKline did not provide a reason for the shortage.

Available Products

    • Sanofi Pasteur has Imovax rabies vaccine available with ordering restrictions. Access post-exposure information via link on the VACCINESHOPPE home page found at
    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Sanofi Pasteur has Imovax rabies vaccine on back order and the company estimates a release date of late-October 2019.
    • GlaxoSmithKline has RabAvert rabies vaccine on back order and the company estimates a release date of quarter 1 of 2020.


Updated October 11, 2019 by Anthony Trovato, PharmD, BCPS. Created September 16, 2019 by Rachael Freeman, PharmD, BCPS. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.


This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins